A Second View: Evaluating the Future Treatment Landscape for Lipoprotein(a) management and the Potential of Pelacarsen (Novartis), Olpasiran (Amgen), and Lepodisiran (Eli Lilly)

Executed on:Apr 22, 2026 3:45 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Penn MedicineClinical Associate Professor at the University of Pennsylvania’s Perelman School of Medicine, specializing in preventive cardiology and clinical lipidology at Penn Heart and Vascular Center.
Manages over 100+ patients for cardiovascular disease
Fellow of the National Lipid Association and American College of Physicians, authoring over 50 peer-reviewed articles on cardiovascular risk and apolipoprotein B management.

Interview Goal

This call will discuss the current treatment landscape for Lipoprotein(a) and the potential of Pelacarsen from Novartis, OLPASIRAN from Amgen, and lepodisiran from Eli Lilly.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.